These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27891769)

  • 1. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.
    Chaudhuri A; Ghanim H; Makdissi A; Green K; Abuaysheh S; Batra M; D Kuhadiya N; Dandona P
    Diabetes Obes Metab; 2017 May; 19(5):729-733. PubMed ID: 27891769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
    Tokuda M; Katsuno T; Ochi F; Miyakoshi K; Kusunoki Y; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2014; 61(4):365-72. PubMed ID: 24452017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
    Dandona P; Chaudhuri A; Dhindsa S
    Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
    Okerson T; Yan P; Stonehouse A; Brodows R
    Am J Hypertens; 2010 Mar; 23(3):334-9. PubMed ID: 20019672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.
    Apovian CM; Bergenstal RM; Cuddihy RM; Qu Y; Lenox S; Lewis MS; Glass LC
    Am J Med; 2010 May; 123(5):468.e9-17. PubMed ID: 20399326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
    Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
    Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
    Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.